Business Description
Cardiff Oncology Inc
NAICS : 325414
SIC : 2836
ISIN : US8972384080
Total Employee Number:
31Description
Cardiff Oncology Inc is a clinical-stage biotechnology company advancing cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Its main asset, onvansertib, is a specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, to overcome treatment resistance and deliver improved clinical outcomes for patients.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 75.54 | |||||
Equity-to-Asset | 0.71 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | -0.01 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -15.51 | |||||
Beneish M-Score | -1.7 | |||||
WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 7.6 | |||||
3-Year EPS without NRI Growth Rate | 8.1 | |||||
3-Year FCF Growth Rate | 10.8 | |||||
3-Year Book Growth Rate | -34.7 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -11.77 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | -26.47 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 55.76 | |||||
9-Day RSI | 52.05 | |||||
14-Day RSI | 47.25 | |||||
3-1 Month Momentum % | -20.36 | |||||
6-1 Month Momentum % | -11.9 | |||||
12-1 Month Momentum % | -45.12 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.3 | |||||
Quick Ratio | 3.3 | |||||
Cash Ratio | 3.2 | |||||
Days Sales Outstanding | 192.85 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -15.2 | |||||
Shareholder Yield % | 0.94 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -8320.08 | |||||
Net Margin % | -7884.06 | |||||
EBITDA Margin % | -8135.43 | |||||
FCF Margin % | -8084.6 | |||||
OCF Margin % | -8084.6 | |||||
ROE % | -93.57 | |||||
ROA % | -69.56 | |||||
ROIC % | -748.71 | |||||
3-Year ROIIC % | 360.16 | |||||
ROC (Joel Greenblatt) % | -3478.68 | |||||
ROCE % | -98.35 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 106.79 | |||||
PB Ratio | 2.48 | |||||
Price-to-Tangible-Book | 2.49 | |||||
EV-to-EBIT | -0.96 | |||||
EV-to-EBITDA | -0.98 | |||||
EV-to-Revenue | 80.13 | |||||
EV-to-Forward-Revenue | 93.36 | |||||
EV-to-FCF | -1 | |||||
Price-to-Median-PS-Value | 0.63 | |||||
| Price-to-Net-Current-Asset-Value | 2.67 | |||||
| Price-to-Net-Cash | 2.76 | |||||
Earnings Yield (Greenblatt) % | -104.17 | |||||
FCF Yield % | -54.64 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cardiff Oncology Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.435 | ||
| EPS (TTM) (€) | -0.517 | ||
| Beta | 2.871 | ||
| 3-Year Sharpe Ratio | 0.25 | ||
| 3-Year Sortino Ratio | 0.61 | ||
| Volatility % | 87.04 | ||
| 14-Day RSI | 47.25 | ||
| 14-Day ATR (€) | 0.039183 | ||
| 20-Day SMA (€) | 0.709325 | ||
| 12-1 Month Momentum % | -45.12 | ||
| 52-Week Range (€) | 0.598 - 2.67 | ||
| Shares Outstanding (Mil) | 77.8 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Cardiff Oncology Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Cardiff Oncology Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-06 | In 82 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-12 16:30 | 0.81 (+0.00%) | ||
| Second quarter earnings results for 2026 | 2026-08-12 | 0.81 (+0.00%) | ||
| General meeting for 2026 | 2026-06-11 08:00 | 1.24 (+0.00%) | ||
| Jefferies Global Healthcare Conference | 2026-06-04 10:30 | 1.22 (-2.16%) | ||
| Updated Phase 2 CRDF-004 Data for Onvansertib in First-Line RAS-Mutated mCRC | 2026-06-03 08:30 | 1.21 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-14 | 1.32 (+0.00%) | ||
| Key Opinion Leader Discussion on Onvansertib\'s Promising Single-Agent Activity | 2026-04-30 11:00 | 1.37 (+0.88%) | ||
| The Emergent Treatment Landscape: First-Line RAS-mutant Metastatic Colorectal Cancer | 2026-03-25 16:30 | 1.46 (+0.00%) | ||
| TD Cowen 46th Annual Health Care Conference | 2026-03-04 11:50 | 1.57 (+0.00%) |
Show
Entries
Cardiff Oncology Inc Frequently Asked Questions
What is Cardiff Oncology Inc(FRA:XE7C)'s stock price today?
The current price of FRA:XE7C is €0.77. The 52 week high of FRA:XE7C is €2.67 and 52 week low is €0.60.
When is next earnings date of Cardiff Oncology Inc(FRA:XE7C)?
The next earnings date of Cardiff Oncology Inc(FRA:XE7C) is 2026-11-06 Est..
Does Cardiff Oncology Inc(FRA:XE7C) pay dividends? If so, how much?
Cardiff Oncology Inc(FRA:XE7C) does not pay dividend.
Press Release
Articles on Cardiff Oncology Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers